MK-2206 2HCl

製品コードS1078

MK-2206 2HCl化学構造

分子量(MW):480.39

MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。

サイズ 価格(税別)  
JPY 36520.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 94620.00

文献中の使用例(180)

カスタマーフィードバック(19)

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

製品安全説明書

Akt阻害剤の選択性比較

生物活性

製品説明 MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。
特性 The first allosteric small molecule inhibitor of Akt to enter clinical development.
ターゲット
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
体外試験

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NUC5TIg1S3m2b4TvfIlkKEG|c3H5 NYLJW2dtOyEQvF2= NWTJXXJ4PzJiaB?= M4\jemROW09? MWnJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MUeyNFU4OTB4OR?=
A431 NFzScINMcW6jc3WgRZN{[Xl? MoTqOUDPxE1? M2q4WlUhcA>? M{fsbmROW09? NY\k[mpEW3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt Mlj1NlA2PzFyNkm=
HepG2 M2nW[2N6fG:2b4jpZ{BCe3OjeR?= NFjNNYsyOCEQvF2= MkDnNlQhcA>? NHrUfGpFVVOR MnLYV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni NVzDboFUOjF{MEW5NlU>
Sk-Hep1 NVLLWo5pS3m2b4TvfIlkKEG|c3H5 MkTsNVAh|ryP MWqyOEBp NVjFZ|d6TE2VTx?= MXLT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NXqyW3NQOjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) M4jLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTLV5BOOyEQvF2= NYDFW5JWPSCm MUDEUXNQ MmjxTWM2OD1yLkG0JO69VQ>? MlXjNlEzQDl{Nke=
K1 cells harbored PIK3CA (E542K+/+) MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHsXZl3OyEQvF2= MlrjOUBl NEnZe5BFVVOR M1H5VGlEPTB;MD61NkDPxE1? M{XYTlIyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) NX3iVG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz3cW41OyEQvF2= M4TOd|Uh\A>? NYPybXIyTE2VTx?= NUm3RnFFUUN3ME2wMlE5KM7:TR?= MVWyNVI5QTJ4Nx?=
C643 cells harbored HRAS (G13R+/−) NFuzd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\QdFMh|ryP NHPCTlI2KGR? M1XMbGROW09? NH3VPYxKSzVyPUCuNlch|ryP NHW1NpYzOTJ6OUK2Oy=>
Hth7 cells harbored NRAS (Q61R+/−) NGq5WZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DSWlMh|ryP M1jyOlUh\A>? MXLEUXNQ MUXJR|UxRTRwNTFOwG0> M2HGXFIyOjh7Mk[3
TPC1 cells harbored RET/PTC1 rearrangement MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7HN{DPxE1? M4T0ZlUh\A>? MYnEUXNQ MXPJR|UxRTBwNUmg{txO MXOyNVI5QTJ4Nx?=
Hth74 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUizJO69VQ>? NXG4fZVrPSCm NVnobYpJTE2VTx?= NH3qcINKSzVyPUKuNVkh|ryP NELyb3czOTJ6OUK2Oy=>
KAT18 M1[wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSzJO69VQ>? NELNfVk2KGR? M4[wT2ROW09? MmW0TWM2OD12Lk[yJO69VQ>? MXeyNVI5QTJ4Nx?=
SW1736 MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPwTJZqOTByIN88US=> NH\TO282KGR? MoHpSG1UVw>? M1rFPGlEPTB;NEeuOVYh|ryP M3PJbFIyOjh7Mk[3
WRO MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M161eFExODBizszN MUS1JIQ> MV\EUXNQ NFvjXmhKSzVyPkGwNFAh|ryP M{DJV|IyOjh7Mk[3
TAD2 NIHOSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy2VnV6OTByMDFOwG0> M1fUSVUh\A>? NIjTfW1FVVOR NFTOVJFKSzVyPkGwNFAh|ryP Ml65NlEzQDl{Nke=
LN229 M{DXN2Fxd3C2b4Ppd{BCe3OjeR?= NXTnUYU4OC53IN88US=> MY[2NEBp M1rGTGROW09? NFrXdo5CfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= M4rqVlIzODV5OUG0
T98G NXuxfId[SXCxcITvd4l{KEG|c3H5 NXfjWIVqOC53IN88US=> MV62NEBp M2LodGROW09? M1HKOWF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk NXLXNGRuOjJyNUe5NVQ>
HC11 M2XCNWZ2dmO2aX;uJGF{e2G7 MX:xNEDPxE1? MV[yOEBp MmeySG1UVw>? M4nKcGlvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> Mn36NlI1OjZ4MkG=
MOLT-4 NX;wUFNNS3m2b4TvfIlkKEG|c3H5 NEnpS5cyOCEQvF2= MWm0PEBp M1XFcmROW09? Mme5TWM2OD1zLkhihKnPxE1? NH3yWWUzOjZzNEK0Ny=>
CEM-R MYfDfZRwfG:6aXOgRZN{[Xl? M1;FelExKM7:TR?= NFvzSnY1QCCq MXXEUXNQ M2OwN2lEPTB;Mz6z5qCK|ryP MVWyNlYyPDJ2Mx?=
CEM-S MXrDfZRwfG:6aXOgRZN{[Xl? NF;OepkyOCEQvF2= NFrZPFM1QCCq MlvKSG1UVw>? NVzZflNqUUN3ME21MlHjiIoQvF2= MWeyNlYyPDJ2Mx?=
MOLT-4 Mk\OSpVv[3Srb36gRZN{[Xl? NEjEeJgyOCEQvF2= MXmyOEBp MXHEUXNQ MnrlRoxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? NGPxUHMzOjZzNEK0Ny=>
MOLT-4 NFvle49HfW6ldHnvckBCe3OjeR?= MlP4OQKBkc7:TR?= M2fjcVQhcA>? M2fXU2ROW09? MlKzTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{PBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz M2KweFIzPjF2MkSz
CEM-R MmrKSpVv[3Srb36gRZN{[Xl? NV6yV4ZFPOLCid88US=> M2H1N|QhcA>? M2POfWROW09? MmTGTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz NXPBXmhiOjJ4MUSyOFM>
CEM-S MYnGeY5kfGmxbjDBd5NigQ>? MYO05qCK|ryP M3e2b|QhcA>? MonuSG1UVw>? NHy2dGNKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? NYnKXGR{OjJ4MUSyOFM>
HepG2 cell MoPyT4lv[XOnIFHzd4F6 MmXENlAh|ryP MWSyOEBp M2HjcGROW09? MWXEc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV NEnKdlIzOzd7N{OxPS=>
HepG2 cell MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;IXWVHOzBizszN MoS2NlQhcA>? M1nsU2ROW09? NUnCXYUzUW6qaXLpeJMh[2WubDDndo94fGh? M1vTb|I{Pzl5M{G5
HepG2 cell M4\YS2Fxd3C2b4Ppd{BCe3OjeR?= NYTFcI56OjBizszN NFrxSngzPCCq M4jVeWROW09? NWi5UHVTUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NH73OW0zOzd7N{OxPS=>
GEO NYLXWnNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDoeoo2ODBibl2= M{TpPFczKGh? MX7EUXNQ NVrGTlVOUW6qaXLpeJMh[2WubDDndo94fGh? NWPYZ2lFOjR3OEGyN|E>
CNE-1 M{HIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnUfplROTBizszN MoDVPVYhcA>? MlTXSG1UVw>? NUjNfZo6UUN3ME2yMlk3KM7:TR?= M1\ZfFI2OzN4OUK1
CNE-2 M{jUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfsNVAh|ryP Mkm0PVYhcA>? NUPhUYNCTE2VTx?= MoHITWM2OD12LkWzJO69VQ>? M1;nW|I2OzN4OUK1
HONE-1 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHB[noyOCEQvF2= M364NVk3KGh? MYXEUXNQ MlviTWM2OD1|LkO3JO69VQ>? NXn3THRQOjV|M{[5NlU>
SUNE-1 NFPaepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmxbJoyOCEQvF2= NUK3blAxQTZiaB?= MV\EUXNQ MmfYTWM2OD1yLkWyJO69VQ>? Ml3ONlU{OzZ7MkW=
CNE-2 MmjvSpVv[3Srb36gRZN{[Xl? NXm2ZXViOTBizszN MoSzOFghcA>? NFPnOGJFVVOR NFL5cJRKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MWSyOVM{Pjl{NR?=
HONE-1 NHHGcYVHfW6ldHnvckBCe3OjeR?= MnXUNVAh|ryP NW\Wb2V2PDhiaB?= M2jjW2ROW09? NHS0cmNKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz NWfHcYRoOjV|M{[5NlU>
NEC8 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rDOWlEPTB;MD6wPVY2OSEQvF2= M1;qTnNCVkeHUh?=
P12-ICHIKAWA NELIWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjMTWM2OD1yLkGxOlIh|ryP NIfSSGlUSU6JRWK=
MDA-MB-175-VII M4jsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS1ZYZKSzVyPUCuNVM4OzhizszN NX;3fIN[W0GQR1XS
AsPC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjQeWVKSzVyPUCuNlIyOjJizszN MUXTRW5ITVJ?
T47D Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TKVGlEPTB;MD6yPFI2KM7:TR?= NVj1NWFQW0GQR1XS
HH NHzpNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnRTpNXUUN3ME2wMlMxOjh|IN88US=> MoDBV2FPT0WU
MOLT-16 NYrIc4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf5fpRmUUN3ME2wMlMxOzJizszN NFHvbnNUSU6JRWK=
ES5 NFPueWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nPcmlEPTB;MD6zOFQ2PSEQvF2= NFTEWm9USU6JRWK=
RS4-11 NVrWXZZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P6[2lEPTB;MD6zOFYyKM7:TR?= M1HIRnNCVkeHUh?=
KARPAS-45 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTwbG9MUUN3ME2wMlM4OzJzIN88US=> NWjIUoV{W0GQR1XS
NCI-H720 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK1TWM2OD1yLkO3Olc6KM7:TR?= NET3OYNUSU6JRWK=
H9 NHjlRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{i4PFMh|ryP NGCxWJlUSU6JRWK=
EFM-19 NFvjWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNESwNUDPxE1? NGXVUmlUSU6JRWK=
SBC-1 M1znWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXXZYxvUUN3ME2wMlQ1ODN3IN88US=> Mn\RV2FPT0WU
A4-Fuk MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjPOHlKSzVyPUCuOFY5PjhizszN MVfTRW5ITVJ?
NCI-H1563 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\4TWM2OD1yLkS4NVg6KM7:TR?= MlSyV2FPT0WU
HCC1419 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S3fWlEPTB;MD60PFg6OiEQvF2= NYH0W25PW0GQR1XS
H-EMC-SS NH[5U5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjwbY5TUUN3ME2wMlQ6QTN7IN88US=> NXXvVo0{W0GQR1XS
BHT-101 M1LYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHONmxKSzVyPUCuOVI6PjFizszN NGnwR4RUSU6JRWK=
IGROV-1 M1TaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNUWyOFkh|ryP NUTGU2RCW0GQR1XS
HGC-27 NUK0TWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPVRYxKSzVyPUCuOVY4QDNizszN NIPRNG9USU6JRWK=
MDA-MB-361 NYSwV2ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzROVhKSzVyPUCuOVc4PjFizszN MoPpV2FPT0WU
KE-37 NYXXOZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WyVmlEPTB;MD61PFI3KM7:TR?= M4PZcHNCVkeHUh?=
HCC70 NHXKPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\qUmlEPTB;MD61PVgzPyEQvF2= M33iTXNCVkeHUh?=
LNCaP-Clone-FGC M4nkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\CR2lEPTB;MD62NVA1QCEQvF2= NF\q[nRUSU6JRWK=
HAL-01 NGnwU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTpNmFKSzVyPUCuOlIyOyEQvF2= NG\STWlUSU6JRWK=
HT MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zpfGlEPTB;MD62N|I{QSEQvF2= MnPiV2FPT0WU
MDA-MB-415 M2Li[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwNkO2NlYh|ryP M1rMOXNCVkeHUh?=
NOS-1 NInlZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD1yLk[zO|I{KM7:TR?= NFPpWXdUSU6JRWK=
DU-145 M{nBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzoSnJKSzVyPUCuOlQ4PDVizszN M2DUWXNCVkeHUh?=
OCUB-M M4P2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nZV2lEPTB;MD63NFk3PiEQvF2= M1;XdXNCVkeHUh?=
VA-ES-BJ NH3hb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LBbGlEPTB;MD63N|AzPSEQvF2= NFzpPItUSU6JRWK=
J-RT3-T3-5 M2rj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH3dJh1UUN3ME2wMlc1PDB|IN88US=> M{XhTnNCVkeHUh?=
MOLT-4 NVfBNYtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;2Ro1KSzVyPUCuPFA2QDJizszN M3e3dXNCVkeHUh?=
NB7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPKTWM2OD1yLkiyOFEyKM7:TR?= NIrveGNUSU6JRWK=
L-363 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqxTWM2OD1yLkizOFQzKM7:TR?= M4HsVXNCVkeHUh?=
NKM-1 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwOE[yOVMh|ryP MlvCV2FPT0WU
HOP-92 M1O2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDLV5F[UUN3ME2wMlg4OjJ|IN88US=> MXfTRW5ITVJ?
OAW-42 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTZVYc2UUN3ME2wMlg5PzJizszN M1OxbnNCVkeHUh?=
HuO9 NHLYXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XFb2lEPTB;MD65Nlc2OSEQvF2= MnLQV2FPT0WU
MFE-280 M4PLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nIUmlEPTB;MD65OlQ3PSEQvF2= NIrE[JVUSU6JRWK=
EM-2 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwOUe5N|kh|ryP NHLMXoRUSU6JRWK=
NCI-H520 M4f2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[0UGlEPTB;MD65PFU6OiEQvF2= NGfNfWFUSU6JRWK=
LB2241-RCC Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXafFZKSzVyPUCuPVk4OzRizszN NYTWR3p[W0GQR1XS
SK-NEP-1 NEHyN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjZdIFkUUN3ME2xMlE1PDh3IN88US=> M1jLN3NCVkeHUh?=
LXF-289 NGDOXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHCSYNxUUN3ME2xMlE4OTV4IN88US=> MWHTRW5ITVJ?
EPLC-272H NVXJ[nVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLuTWM2OD1zLkG3NlU3KM7:TR?= MUTTRW5ITVJ?
COLO-684 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHwNJp{UUN3ME2xMlI{PzJ3IN88US=> M2\rNnNCVkeHUh?=
ES1 NYj5cplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rNTWlEPTB;MT6yOFA3PSEQvF2= M2[0NHNCVkeHUh?=
DOHH-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL2TWM2OD1zLkK4NlA{KM7:TR?= MoX0V2FPT0WU
CTB-1 M1TQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm4TWM2OD1zLkK4PVkh|ryP NVXKb4NDW0GQR1XS
G-401 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwMkm3PVUh|ryP MlvWV2FPT0WU
LoVo MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K0ZmlEPTB;MT6zNlU{PCEQvF2= M1XufXNCVkeHUh?=
Ramos-2G6-4C10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme2TWM2OD1zLkOzO|AyKM7:TR?= NX\YO3hEW0GQR1XS
MFM-223 NWjRd483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvkTYYzUUN3ME2xMlM1PDZzIN88US=> M2Hte3NCVkeHUh?=
PA-1 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwM{WyOlUh|ryP NUH4OmM4W0GQR1XS
697 M{XmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT3ZpRiUUN3ME2xMlM4PjF4IN88US=> NVPsNHU2W0GQR1XS
QIMR-WIL M361Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jFNmlEPTB;MT60PVEyPiEQvF2= MoWzV2FPT0WU
HOS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLhTWM2OD1zLkS5OVU5KM7:TR?= MlLTV2FPT0WU
DMS-273 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\vWohKSzVyPUGuOVE6PTlizszN NYPWVXNPW0GQR1XS
ME-180 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH1TWM2OD1zLkW2PFkyKM7:TR?= NIjWNYxUSU6JRWK=
HCC2218 NX7D[3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzeXZGUUN3ME2xMlY5OjJ3IN88US=> MXrTRW5ITVJ?
CAL-54 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwN{GyOFIh|ryP NXrl[IR3W0GQR1XS
OMC-1 NGTYNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HFXGlEPTB;MT63OFY4PyEQvF2= NXn2O2Y2W0GQR1XS
COR-L105 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkizTWM2OD1zLke5O|M4KM7:TR?= MUDTRW5ITVJ?
BV-173 NU\XeJNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33rWGlEPTB;MT64NVA4PCEQvF2= MknoV2FPT0WU
RKO MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnXWYlZUUN3ME2xMlg4OTBzIN88US=> MYTTRW5ITVJ?
SNU-387 NY\Ce3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XONmlEPTB;MT64PFQxPiEQvF2= NFGzXVVUSU6JRWK=
SW1088 NUXKcYZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnTTWM2OD1zLkm0OlA3KM7:TR?= MlvrV2FPT0WU
Hs-578-T M1f6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;1PYZKSzVyPUKuNVE1OzNizszN MU\TRW5ITVJ?
OC-314 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfNboZKSzVyPUKuNVUxQDZizszN NHnPS45USU6JRWK=
RMG-I M{fkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwMU[zPVgh|ryP NUC3VVI{W0GQR1XS
NCI-H1395 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fYT2lEPTB;Mj6xPFA6OSEQvF2= MnH4V2FPT0WU
GAMG NHjGXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OxRWlEPTB;Mj6yN|g1PSEQvF2= MXrTRW5ITVJ?
LB1047-RCC MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\OTWM2OD1{LkK0N|E4KM7:TR?= NVfwUnZiW0GQR1XS
MN-60 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG3emxKSzVyPUKuNlk6OjNizszN MnfzV2FPT0WU
OAW-28 NVrXS3hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmyTWM2OD1{LkK5PVUyKM7:TR?= M1n0W3NCVkeHUh?=
NCI-H2228 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLienpKSzVyPUKuN|E2PTJizszN NHO5[WxUSU6JRWK=
ABC-1 M1\ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n3OGlEPTB;Mj6zN|I2OyEQvF2= MVXTRW5ITVJ?
LS-513 NF3CZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfZbZVrUUN3ME2yMlM{PDh2IN88US=> MWLTRW5ITVJ?
KS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\jWWkxUUN3ME2yMlM5OTlzIN88US=> MXLTRW5ITVJ?
NB69 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fTUWlEPTB;Mj6zPFk5OyEQvF2= M4DKd3NCVkeHUh?=
VM-CUB-1 NYnNXIF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W0W2lEPTB;Mj6zPVA5OyEQvF2= NWnqR5V2W0GQR1XS
D-423MG Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJwNEGwOFQh|ryP M36yO3NCVkeHUh?=
EW-18 M3HvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3TTWM2OD1{LkSxPVM6KM7:TR?= NVy5OHVWW0GQR1XS
YH-13 NU\COWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3cI5KSzVyPUKuOFYyPTNizszN NY\KdY5UW0GQR1XS
T-24 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC0TWM2OD1{LkS3PFgyKM7:TR?= MVvTRW5ITVJ?
ES8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwNEmyPFch|ryP MXLTRW5ITVJ?
ES3 M4T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJwNEm3OVkh|ryP MmP6V2FPT0WU
RXF393 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXxTWM2OD1{Lk[wOFg4KM7:TR?= NET6bpJUSU6JRWK=
RPMI-8226 NWPV[pNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j1SGlEPTB;Mj62Nlk2OyEQvF2= NH34dIFUSU6JRWK=
AGS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PvV2lEPTB;Mj63NlE{PyEQvF2= MYDTRW5ITVJ?
HCC1395 NFTBTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfrTWM2OD1{Lke1NVg4KM7:TR?= MY\TRW5ITVJ?
MV-4-11 NEP6S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO0b|JKSzVyPUKuO|UzPjZizszN MkTwV2FPT0WU
A204 M3vmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXsd4hWUUN3ME2yMlg{QDd{IN88US=> MU\TRW5ITVJ?
MCF7 M3jLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwOE[xNVch|ryP M1rtd3NCVkeHUh?=
SNU-423 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jsTGlEPTB;Mj64PVI1OiEQvF2= MV3TRW5ITVJ?
NCI-H1048 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwOU[4OlUh|ryP M1HOcHNCVkeHUh?=
GR-ST NXXySHVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TJR2lEPTB;Mz6wOFYyOSEQvF2= NGHCWIFUSU6JRWK=
EoL-1- M{T6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwMEewOVgh|ryP MW\TRW5ITVJ?
HuH-7 NXfHWogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNwMEm0OlQh|ryP M3nEVnNCVkeHUh?=
OS-RC-2 M1;mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ftdmlEPTB;Mz6xNVE6KM7:TR?= NG\JdHhUSU6JRWK=
EW-3 NXjZcnBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwMUm1Nlkh|ryP MVfTRW5ITVJ?
NCI-H747 M3r0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnZfWN2UUN3ME2zMlIxPjl2IN88US=> MVXTRW5ITVJ?
EW-16 NGDBSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNwMkG4O|kh|ryP MV7TRW5ITVJ?
DOK MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH6TWM2OD1|LkKyPFU6KM7:TR?= NGf0UZZUSU6JRWK=
HCC2157 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzSo5KSzVyPUOuN|gyPzlizszN M{TRbHNCVkeHUh?=
OVCAR-3 M1G1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X5O2lEPTB;Mz60NFc5PiEQvF2= MYDTRW5ITVJ?
NCI-H1623 NH;RfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4juc2lEPTB;Mz60NVIzPCEQvF2= MULTRW5ITVJ?
H4 NGrRRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGzSoVKSzVyPUOuOFU3OjZizszN NFPVe5BUSU6JRWK=
SW1710 M{fYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TOZmlEPTB;Mz60OlY4QCEQvF2= Mn[xV2FPT0WU
RT-112 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr2SHJKSzVyPUOuOVI{QDhizszN NX3STJFLW0GQR1XS
DMS-114 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jxbmlEPTB;Mz62NlI4QCEQvF2= M1rCR3NCVkeHUh?=
AN3-CA MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXztW4E5UUN3ME2zMlYzPDV4IN88US=> NIm2O|BUSU6JRWK=
KNS-62 NUix[pU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHWbFZnUUN3ME2zMlY{OzN6IN88US=> NF74cJVUSU6JRWK=
SJRH30 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvyPYdOUUN3ME2zMlY6OTJ{IN88US=> MW\TRW5ITVJ?
G-402 NIXkZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fPd2lEPTB;Mz63NFcyOSEQvF2= M1PWSXNCVkeHUh?=
MHH-PREB-1 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf0TWM2OD1|LkeyNFM5KM7:TR?= MWTTRW5ITVJ?
P30-OHK MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi1TWM2OD1|LkiwPVc3KM7:TR?= MlHHV2FPT0WU
RVH-421 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X2[2lEPTB;Mz64NVc5QCEQvF2= NVnuVIZHW0GQR1XS
LU-134-A NUTOWVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DYU2lEPTB;Mz64PFQzQCEQvF2= MXzTRW5ITVJ?
ECC10 NEfsfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNwOUO2NlIh|ryP M{nFcHNCVkeHUh?=
TGW MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofhTWM2OD12LkCyN|A2KM7:TR?= MUXTRW5ITVJ?
MLMA M1PNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj0TWM2OD12LkCyPVY3KM7:TR?= NFjVOlRUSU6JRWK=
SCC-25 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;h[GlEPTB;ND6wOlU3PiEQvF2= Ml7mV2FPT0WU
TYK-nu NFKySnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVezcXg1UUN3ME20MlA6PTN2IN88US=> NXLOXHVzW0GQR1XS
LAMA-84 M2nFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i0[mlEPTB;ND6xOFE6OSEQvF2= NY\kfVQ{W0GQR1XS
Calu-3 NYSyNJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnMTWM2OD12LkK0OFE3KM7:TR?= NHLCZ3BUSU6JRWK=
NCI-H460 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHRcIVKSzVyPUSuNlY1PDNizszN M2G5WHNCVkeHUh?=
EGI-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HQOWlEPTB;ND6zO|c4QCEQvF2= NXTC[ZJMW0GQR1XS
NCI-H292 NXfwd4k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LwXmlEPTB;ND6zPFE1PiEQvF2= MYrTRW5ITVJ?
HCE-T M3L5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy3UVlMUUN3ME20MlQyPTd7IN88US=> MmjsV2FPT0WU
EW-11 NGPIR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwNEG4N|gh|ryP NHrjSmRUSU6JRWK=
ATN-1 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LP[2lEPTB;ND60OFMxPCEQvF2= NVjyR2lDW0GQR1XS
NB5 NEX1SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRwNUO2PVch|ryP MU\TRW5ITVJ?
KLE MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5PWlEPTB;ND63NFE6QCEQvF2= M1;NdHNCVkeHUh?=
CAL-39 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID3cHBKSzVyPUSuO|IyPDZizszN NVnZTY1vW0GQR1XS
TI-73 M3\nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRwOEC2NFkh|ryP MofEV2FPT0WU
HO-1-N-1 NF\GNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRwOUSyJO69VQ>? NWLwcHY6W0GQR1XS
786-0 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXq[4lKSzVyPUSuPVQ3PzNizszN NGH2OopUSU6JRWK=
SK-N-DZ NVTn[ppST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HTTmlEPTB;ND65OlE1OiEQvF2= M1;ON3NCVkeHUh?=
NCI-H446 M17lUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni1TWM2OD13LkKwNFA6KM7:TR?= M4T0UnNCVkeHUh?=
ETK-1 NFPMPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXR[XVKSzVyPUWuNlEyPjVizszN MYTTRW5ITVJ?
BT-20 NUPNPVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwMkGzOVMh|ryP M2\L[nNCVkeHUh?=
MEL-HO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TqdWlEPTB;NT6zO|M{PiEQvF2= NFLVToZUSU6JRWK=
CAL-27 NYriNpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwNE[zN|kh|ryP MVnTRW5ITVJ?
SW872 NEfwcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTVwNUm0Nlgh|ryP M1HiWXNCVkeHUh?=
RPMI-2650 M2O4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW3PIxwUUN3ME21MlY3OTl7IN88US=> NHvmcJlUSU6JRWK=
PFSK-1 NIDkUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK4TWM2OD13LkeyO|MzKM7:TR?= NHr2R4RUSU6JRWK=
SF295 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fyTGlEPTB;NT64NFY{OyEQvF2= MX;TRW5ITVJ?
Becker MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD13Lki2OFczKM7:TR?= MUXTRW5ITVJ?
Saos-2 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULLSldOUUN3ME21Mlg3PTNizszN MWrTRW5ITVJ?
SK-OV-3 NVvvO2M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwOUm4NVYh|ryP MnPUV2FPT0WU
VMRC-RCZ NIPaPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMTWM2OD14LkC4O|c{KM7:TR?= MmLmV2FPT0WU
EW-22 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZwMUm2OFkh|ryP M3Oy[HNCVkeHUh?=
BT-474 NFLpVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnsdVJKSzVyPU[uNlM{KM7:TR?= MW\TRW5ITVJ?
BFTC-909 NFnqSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HUbWlEPTB;Nj6zNFM1PSEQvF2= M2nab3NCVkeHUh?=
NB12 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;LRWlEPTB;Nj6zPVA4OSEQvF2= MVjTRW5ITVJ?
D-263MG M{D0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv4OoFKSzVyPU[uOFUyPjlizszN M1;R[HNCVkeHUh?=
SNB75 M1juSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG1OGtKSzVyPU[uOlAyPDNizszN MnHpV2FPT0WU
A704 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZwNkOwOkDPxE1? MUDTRW5ITVJ?
NCI-H1693 NIDPSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37y[WlEPTB;Nj62N|YxPCEQvF2= MVHTRW5ITVJ?
LN-405 NELyc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2y[2RKSzVyPU[uO|k3PzJizszN M4PmbXNCVkeHUh?=
CHL-1 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL2TWM2OD14LkiwNFc6KM7:TR?= NY[yeZkxW0GQR1XS
A498 NI\aOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTZwOEG5OlEh|ryP NIHKco9USU6JRWK=
TE-12 M1P5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\0TWM2OD14LkizPFE4KM7:TR?= MUfTRW5ITVJ?
TE-6 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPITWM2OD14LkmzNFM5KM7:TR?= NG\DPWVUSU6JRWK=
AU565 M17xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL1[5NKSzVyPU[uPVY6PTdizszN MmLPV2FPT0WU
RD MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX3TWM2OD14Lkm4Nlg1KM7:TR?= NF7vOHNUSU6JRWK=
SW1463 M1vre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS3XXB3UUN3ME23MlEyOTZ6IN88US=> NFXm[ZhUSU6JRWK=
LU-99A Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET3c3pKSzVyPUeuNVQ{OjJizszN M2\IXXNCVkeHUh?=
NCI-H28 M13nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS2TWM2OD15LkK5NlQh|ryP MkP6V2FPT0WU
MC-IXC NWPuVHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTdwNEi1O|Yh|ryP NXvkSVdiW0GQR1XS
GP5d MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXMR3lLUUN3ME23MlQ5PzZ2IN88US=> NIjUV2JUSU6JRWK=
GB-1 NHfud4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ER4t7UUN3ME23MlU1QDB2IN88US=> MUnTRW5ITVJ?
CAL-33 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTdwNk[yN|Mh|ryP M37YfXNCVkeHUh?=
MSTO-211H M1iwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\MOmlEPTB;Nz62O|M{PiEQvF2= NY\wXG9UW0GQR1XS
TE-5 NVvEb|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi0[3ZqUUN3ME23Mlc6OzN2IN88US=> MWrTRW5ITVJ?
D-566MG M{nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOyfol7UUN3ME24MlA1PDJ7IN88US=> MUfTRW5ITVJ?
JVM-3 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRThwMUWyOlgh|ryP MVHTRW5ITVJ?
T98G M1rMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\MNo94UUN3ME24MlE5ODZ5IN88US=> NXjMeJV6W0GQR1XS
HCC1954 NWmxXYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITEW3VKSzVyPUiuOFUyODRizszN M1;QbXNCVkeHUh?=
SF126 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Pc5FWUUN3ME24MlQ2QTN4IN88US=> NVLUb|lzW0GQR1XS
LB996-RCC M1\P[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDTTWM2OD16LkWzNlU4KM7:TR?= NXfYOoNiW0GQR1XS
SKG-IIIa M3nvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XkT2lEPTB;OD62N|A3QSEQvF2= MXzTRW5ITVJ?
NCI-SNU-1 NHvGRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLrTWM2OD16Lk[0OlQ{KM7:TR?= M{LMZ3NCVkeHUh?=
LB771-HNC MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwNkS2PVYh|ryP NH;YUlVUSU6JRWK=
SCC-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRThwNkiyNVkh|ryP MWjTRW5ITVJ?
CAMA-1 NVzJR3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX5SJBmUUN3ME24Mlc4OTR4IN88US=> MYPTRW5ITVJ?
D-502MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljJTWM2OD16Lke4OlI6KM7:TR?= MlLlV2FPT0WU
ESS-1 NX3hZo5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{exdmlEPTB;OD64PFcxPCEQvF2= M1;wWHNCVkeHUh?=
HEC-1 NV\yVlJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvhc3ZKSzVyPUiuPFk5PjZizszN MlnCV2FPT0WU
NB10 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLSSFBKSzVyPUmuNFIzOjRizszN NFz3T2JUSU6JRWK=
8505C MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTlwMESyN|Ih|ryP NF:wRYdUSU6JRWK=
EFO-27 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\zb5pKSzVyPUmuNVY1OTJizszN NGrIW5pUSU6JRWK=
HN M1nIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTlwMU[2Nlgh|ryP M{\nU3NCVkeHUh?=
DSH1 NIDncVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTlwMkC4O{DPxE1? NGfuNoRUSU6JRWK=
NBsusSR NVTTRnVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXKeFJKSzVyPUmuNlc1ODJizszN M2nFdnNCVkeHUh?=
LS-123 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\BW5hKSzVyPUmuN|E4PjFizszN M{O4[3NCVkeHUh?=
SHP-77 NE\iT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTlwM{m5N|Uh|ryP NFG2Z4ZUSU6JRWK=
ACN NXnpTZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnuTWM2OD17LkWzNlc4KM7:TR?= NX\rUmVSW0GQR1XS
U251 NFnyNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrWXnNbUUN3ME25MlY2PTR2IN88US=> Mn6xV2FPT0WU
A431 NWjtNot1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jZeGlEPTB;OT64NFI{QCEQvF2= NH\PdpdUSU6JRWK=
5637 M17kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwOES5PFQh|ryP NX;MZoVqW0GQR1XS
MDA-MB-157 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTlwOUK4O|gh|ryP NWfZWVM4W0GQR1XS
A101D NIG1UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPjTWM2OD17Lkm5PVc1KM7:TR?= MVXTRW5ITVJ?
YKG-1 NYPJcYJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\kfYU{UUN3ME2xNE4zODB4IN88US=> MVjTRW5ITVJ?
LAN-6 NWfDc3Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVexOHdnUUN3ME2xNE4zOTZ2IN88US=> NEf0OVVUSU6JRWK=
OVCAR-5 NYfWW3huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFyLkK0N|Mh|ryP MmPsV2FPT0WU
A549 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD0SJBDUUN3ME2xNE4{QTd|IN88US=> MVfTRW5ITVJ?
no-11 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3OTWM2OD1zMD60N|U{KM7:TR?= MoXMV2FPT0WU
SF539 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW4SG1KSzVyPUGwMlkxPDFizszN NEHOVpBUSU6JRWK=
A388 NFfpW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\NRYlKSzVyPUGxMlM5QTdizszN NHL1RZJUSU6JRWK=
DEL NXTMdGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFzLkSyOEDPxE1? MYXTRW5ITVJ?
SW954 NX3HdnZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzkTWM2OD1zMT60OlY5KM7:TR?= NWjqbXdCW0GQR1XS
TK10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjCR2tKSzVyPUGxMlUzPzFizszN M1nnPXNCVkeHUh?=
SW756 M{TEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFzLkWyPVQh|ryP MYLTRW5ITVJ?
PC-3 NVPxZ4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzLkW3OlQh|ryP MYLTRW5ITVJ?
ONS-76 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjDTWM2OD1zMT62N|Yh|ryP NYD6c29sW0GQR1XS
A427 M3zXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fzfGlEPTB;MUGuO|A6OyEQvF2= NXnwU4k4W0GQR1XS
MEG-01 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorkTWM2OD1zMT63OVA6KM7:TR?= MV;TRW5ITVJ?
BB30-HNC Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFzLke5PFIh|ryP NUHXS2ZIW0GQR1XS
NCI-H1299 NGfVWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH6TWM2OD1zMT64NFk{KM7:TR?= M4\ZeXNCVkeHUh?=
GCT M3\3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTTWM2OD1zMT64NlI5KM7:TR?= MY\TRW5ITVJ?
D-247MG M3PFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhTWM2OD1zMT65OlY{KM7:TR?= MWPTRW5ITVJ?
CFPAC-1 M3KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDucGVsUUN3ME2xNU46Pzh{IN88US=> M{LxeXNCVkeHUh?=
EKVX M4rmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULZeZJ[UUN3ME2xNk4xOzF|IN88US=> M3f2THNCVkeHUh?=
CAL-51 M4DjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LOcGlEPTB;MUKuNFcyPiEQvF2= M33xV3NCVkeHUh?=
BB49-HNC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv2RpdKSzVyPUGyMlEyPzdizszN MXzTRW5ITVJ?
RPMI-7951 NH;xW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjrXY8xUUN3ME2xNk4yQDV2IN88US=> NIT4V5FUSU6JRWK=
RH-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK4UGdKSzVyPUGyMlIyQDRizszN MUDTRW5ITVJ?
BCPAP NXixSpZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF{LkS3OFkh|ryP MmXnV2FPT0WU
GCIY M3Tqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkWyNFkh|ryP NXXhUlh7W0GQR1XS
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF{LkW4Olkh|ryP MUPTRW5ITVJ?
KYSE-140 M4nkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDWS2xKSzVyPUGyMlg2QTVizszN M2Th[XNCVkeHUh?=
Ca-Ski NELDd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXzfXRYUUN3ME2xNk46ODRzIN88US=> MnHVV2FPT0WU
TGBC1TKB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfXclVKSzVyPUGyMlkyOTVizszN NUHVNlNsW0GQR1XS
HCC1187 NVjGOGg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzUeHlKSzVyPUGzMlE6OTJizszN M3\XWnNCVkeHUh?=
SJSA-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELtNVhKSzVyPUGzMlI{OjdizszN MX;TRW5ITVJ?
CTV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe5PJBKSzVyPUGzMlM1PSEQvF2= NX60SZpUW0GQR1XS
WM-115 NY\pN2RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCySW1VUUN3ME2xN{43PDh|IN88US=> MmnDV2FPT0WU
CHP-212 NFj6Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnlPHdSUUN3ME2xN{46PzN7IN88US=> MnXzV2FPT0WU
SCC-15 NHq4cpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3TmlEPTB;MUOuPVc4PSEQvF2= NH7nfY1USU6JRWK=
BPH-1 NGjBdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HEN2lEPTB;MUSuNVY3PCEQvF2= NH75V3NUSU6JRWK=
SW780 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnlNHIyUUN3ME2xOE42ODJ3IN88US=> MlHQV2FPT0WU
NCI-H2291 M3rE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzvbXZKUUN3ME2xOE42QDd6IN88US=> NULRdXZVW0GQR1XS
JEG-3 M2XwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\vXnZyUUN3ME2xOE43OzJ4IN88US=> M3fPdnNCVkeHUh?=
CAL-120 NYDhUnJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF2LkewNlch|ryP NIPUTXJUSU6JRWK=
NCI-H23 M2DzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITtTIdKSzVyPUG0Mlc6QTdizszN NULjO3dGW0GQR1XS
MS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPOb2VKSzVyPUG0Mlk3OTFizszN NX;BTXc5W0GQR1XS
PC-14 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zGZ2lEPTB;MUSuPVY2PCEQvF2= NHHlUnZUSU6JRWK=
D-283MED MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTYbFNrUUN3ME2xOU4xOTFzIN88US=> NIDoV5JUSU6JRWK=
OE19 M1[3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF3LkG1OFEh|ryP NYKxOoc{W0GQR1XS
CAS-1 M{HxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF3LkSxPFQh|ryP Mmm3V2FPT0WU
NCI-H727 M4flTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGyTWM2OD1zNT60NlIyKM7:TR?= NFPzTnhUSU6JRWK=
SiHa MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP5TWM2OD1zNT63OVk1KM7:TR?= NF:wcYlUSU6JRWK=
BFTC-905 NH3teGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF3Lke2PVQh|ryP NUXzR|VHW0GQR1XS
MDA-MB-453 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF4LkG2OFIh|ryP MX\TRW5ITVJ?
HuP-T3 NVLKNWFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonYTWM2OD1zNj62N|c{KM7:TR?= MYfTRW5ITVJ?
SK-LU-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorpTWM2OD1zNj62PVU3KM7:TR?= NUjVTXppW0GQR1XS
Detroit562 NHe4UZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PQWGlEPTB;MU[uO|MyQCEQvF2= NYjpdHRKW0GQR1XS
HCC1569 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3lNI9KSzVyPUG2Mlg{OzdizszN NWTJOIM1W0GQR1XS
SK-MES-1 NYPqTHBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PESGlEPTB;MU[uPFQyQSEQvF2= M2rvdXNCVkeHUh?=
BB65-RCC MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF5LkC0O|kh|ryP NVnKPWpLW0GQR1XS
LOXIMVI MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC4OWRKSzVyPUG3MlA4ODdizszN M1mwR3NCVkeHUh?=
SW1783 NEi5[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfMempOUUN3ME2xO{4yOjhizszN NV\ido9tW0GQR1XS
NH-12 NW\iOlFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\S[GlEPTB;MUeuN|MxOyEQvF2= MmnIV2FPT0WU
UACC-257 M4PIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n3emlEPTB;MUeuOVUyOiEQvF2= M2DpcnNCVkeHUh?=
KOSC-2 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDXTWM2OD1zNz62O|U4KM7:TR?= M3PKXXNCVkeHUh?=
KG-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HkVGlEPTB;MUeuOlk{PyEQvF2= NYTuOIVxW0GQR1XS
M059J Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rQTmlEPTB;MUeuO|A{KM7:TR?= MYHTRW5ITVJ?
MHH-NB-11 NW[1OmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF5Lkm2O|Mh|ryP MlTaV2FPT0WU
EW-1 NHm2W4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjCTWM2OD1zOD6xN|gzKM7:TR?= NF7O[WtUSU6JRWK=
CAL-85-1 NXGxOnZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7HdFlKUUN3ME2xPE4zOzV5IN88US=> MmDzV2FPT0WU
639-V NWjrcZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzsW45KSzVyPUG4MlM{PTRizszN NYnY[3l4W0GQR1XS
C32 M{jLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT4UY9KSzVyPUG4MlQ4OjdizszN NVTIe4FKW0GQR1XS
KM-H2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXlUIpKUUN3ME2xPE42OjN{IN88US=> Mn;yV2FPT0WU
A253 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv4[pRtUUN3ME2xPE44Ojh4IN88US=> M17GS3NCVkeHUh?=
NCI-N87 NIrJOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jjeGlEPTB;MUiuPVAxQCEQvF2= M1GySXNCVkeHUh?=
8-MG-BA NWLqOHZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPJTWM2OD1zOT6wOlQ3KM7:TR?= NF\kcINUSU6JRWK=
GI-ME-N MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLaeVVoUUN3ME2xPU4yPTR4IN88US=> NFfhNWZUSU6JRWK=
8305C NFT5[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojqTWM2OD1zOT6yNlg3KM7:TR?= MUTTRW5ITVJ?
TE-8 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF7LkOwNlQh|ryP MY\TRW5ITVJ?
KYSE-270 NV3yS5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJyLkCyNVch|ryP NGLoNmdUSU6JRWK=
HL-60 NEjhbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfCSlI2UUN3ME2yNE4xQTRzIN88US=> MlflV2FPT0WU
Mo-T MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfkW49KSzVyPUKwMlE3PjVizszN M1\uOnNCVkeHUh?=
NCI-H1355 M3LjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJyLkOzO|Qh|ryP NW\F[GVNW0GQR1XS
HT-1080 NHXRXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTtZoFWUUN3ME2yNE42PDl5IN88US=> MnX0V2FPT0WU
MIA-PaCa-2 M3HxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO5SZNlUUN3ME2yNE43QDh|IN88US=> MlrGV2FPT0WU
NCI-H441 NX\FUo03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG2U2JvUUN3ME2yNE44Ozd7IN88US=> NHO3UXpUSU6JRWK=
LCLC-97TM1 NUXEVIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjT[WQ1UUN3ME2yNE45OTN2IN88US=> Mlq5V2FPT0WU
HT-3 NVez[JdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJzLkW2N|Eh|ryP MkLwV2FPT0WU
22RV1 M4PWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD1{MT61Olg2KM7:TR?= M1f1[HNCVkeHUh?=
LK-2 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYZlZOUUN3ME2yNU42QTV|IN88US=> NYnrS3RuW0GQR1XS
CW-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlUoNKSzVyPUKxMlYxPjlizszN NUHGT3BOW0GQR1XS
KYSE-510 NETsdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HYbmlEPTB;MkGuOlA6PSEQvF2= M2HKNXNCVkeHUh?=
CGTH-W-1 NFTvXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJzLkexOlYh|ryP NIj1VHFUSU6JRWK=
NCI-H661 M3flcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG5TWM2OD1{Mj6wN|Qh|ryP NXf2XoJ7W0GQR1XS
KU-19-19 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ{LkG2PVch|ryP NInrU4lUSU6JRWK=
NCI-H2122 NWjlTol1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TGUmlEPTB;MkKuNlQ{OiEQvF2= M{XvUXNCVkeHUh?=
NCI-H526 M2jUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ{LkO4PVUh|ryP NUe0OpVpW0GQR1XS
NCI-H1650 NFXJfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjtdoZKSzVyPUKyMlc3PCEQvF2= MYrTRW5ITVJ?
AM-38 NVL4PHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDDUopCUUN3ME2yNk45Pjh7IN88US=> MnvlV2FPT0WU
NCI-H2405 NVzaXlRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ|LkK1N|Mh|ryP M3rubXNCVkeHUh?=
M14 NWr4XJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ|LkSwPFgh|ryP NF;RNWpUSU6JRWK=
ES4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\VW|N[UUN3ME2yN{41OjN{IN88US=> M1\i[3NCVkeHUh?=
DJM-1 NVr0[|N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LDb2lEPTB;MkOuOVI{PCEQvF2= NGPZZ3dUSU6JRWK=
S-117 NVrVUGNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3p[2puUUN3ME2yN{44PjVzIN88US=> MX7TRW5ITVJ?
MZ2-MEL NUP5R4Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\1TWM2OD1{Mz63O|U6KM7:TR?= NXuyN4JZW0GQR1XS
SK-MEL-2 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRSlNKSzVyPUKzMlgyOzNizszN NWnTNFhVW0GQR1XS
HCC1806 M{TkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfMc4hMUUN3ME2yN{45PzB7IN88US=> MoTsV2FPT0WU
NMC-G1 NGPDSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37JcGlEPTB;MkSuNlIzPiEQvF2= M{POPXNCVkeHUh?=
DK-MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ2LkK5OEDPxE1? MmDwV2FPT0WU
SK-N-FI NH7XSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ2LkOzNFIh|ryP M2D4NHNCVkeHUh?=
KINGS-1 NHLyWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rBemlEPTB;MkSuOFg4PCEQvF2= MkPMV2FPT0WU
HCC2998 M1Ht[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT2T5JKSzVyPUK0MlQ5QDVizszN MlO0V2FPT0WU
ALL-PO MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj6S3dKSzVyPUK0MlYyQSEQvF2= M4\0THNCVkeHUh?=
MPP-89 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDRTYFRUUN3ME2yOU4xPDV6IN88US=> NX\aUGc3W0GQR1XS
NCI-H2342 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX1clBKSzVyPUK1MlE6PTNizszN MYrTRW5ITVJ?
TE-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\EWGlEPTB;MkWuN|U3OyEQvF2= M3z3d3NCVkeHUh?=
RH-18 NIPFflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDMboR2UUN3ME2yOU42QTF6IN88US=> MonuV2FPT0WU
HT-1376 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vrVGlEPTB;MkWuOlQ3PSEQvF2= NYHadVFtW0GQR1XS
U-2-OS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD1{NT62PFg5KM7:TR?= NHrPeFZUSU6JRWK=
BT-549 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zCTmlEPTB;MkWuPVAyOSEQvF2= NGH0WmtUSU6JRWK=
NCI-H1755 NH3LTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonwTWM2OD1{NT65PVQ2KM7:TR?= NV3w[nlkW0GQR1XS
EW-13 NXTaR|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzZTWM2OD1{Nj6wNlc1KM7:TR?= NH33SFVUSU6JRWK=
NB13 NXPufIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ4LkC5OFkh|ryP MX3TRW5ITVJ?
NUGC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO3O2xLUUN3ME2yOk4zOTB|IN88US=> M2jDRXNCVkeHUh?=
GMS-10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vBVmlEPTB;Mk[uNlM2OyEQvF2= Mlz5V2FPT0WU
CHP-134 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[5TWM2OD1{Nj6zPFY4KM7:TR?= MkntV2FPT0WU
SW962 NWLBbohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;FTWM2OD1{Nj61NFIyKM7:TR?= NX2zWIJmW0GQR1XS
SNU-449 M3nPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\tc456UUN3ME2yO{4xQDB|IN88US=> NUDD[Hd4W0GQR1XS
HuP-T4 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLOTWM2OD1{Nz6wPFc6KM7:TR?= NITSe4VUSU6JRWK=
SW948 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW5TWM2OD1{Nz6xN|Q1KM7:TR?= MYXTRW5ITVJ?
NCI-H226 M4T0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHPU2RTUUN3ME2yO{41PTd6IN88US=> NXLyWnRuW0GQR1XS
SK-PN-DW NYfpbIF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ5Lk[wNVIh|ryP M4XqW3NCVkeHUh?=
GI-1 NVvPTGhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;kOGlEPTB;MkeuO|IyKM7:TR?= NFrFZ3ZUSU6JRWK=
CAL-12T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XtUmlEPTB;MkiuNVEyOiEQvF2= NWPGbIR{W0GQR1XS
YAPC NUPO[29TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ6LkK1OlQh|ryP MX\TRW5ITVJ?
SNU-C2B M1[0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXnV4xiUUN3ME2yPE4zQTZ2IN88US=> NXmyNJdQW0GQR1XS
RCC10RGB NF;XWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i2UGlEPTB;MkiuOVQyPyEQvF2= NFjXSXpUSU6JRWK=
ES7 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XBXGlEPTB;MkmuNVQ3PSEQvF2= NXq5cZVsW0GQR1XS
PANC-03-27 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7MNnhHUUN3ME2yPU41PDRizszN MkfCV2FPT0WU
ES6 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHve4RKSzVyPUK5MlgyPTdizszN MXrTRW5ITVJ?
HT-1197 M1exSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNyLkC1PVgh|ryP NVrxdVFbW0GQR1XS
ZR-75-30 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3V|NKSzVyPUOwMlI{QDNizszN MYTTRW5ITVJ?
DB M1u1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHzTWM2OD1|MD60PVQzKM7:TR?= M3:xRnNCVkeHUh?=
OCI-AML2 M1XoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNzLkC2PUDPxE1? NIj6SIlUSU6JRWK=
NCI-H2170 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLLTWM2OD1|MT64OVE3KM7:TR?= NWG5NIdRW0GQR1XS
IST-MES1 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN{LkK4PVch|ryP M4\DbnNCVkeHUh?=
769-P NVfyfWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\YbWlEPTB;M{KuN|Y1OSEQvF2= M1jlb3NCVkeHUh?=
COR-L23 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrWTWM2OD1|Mj65NFc{KM7:TR?= MmO0V2FPT0WU
SW626 NGrRRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT4dWt[UUN3ME2zN{4yPzd4IN88US=> MVfTRW5ITVJ?
LU-139 NVLWbJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP3TWM2OD1|Mz62OlA2KM7:TR?= NX7EcnlsW0GQR1XS
HT-144 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[w[YtKSzVyPUOzMlg3OyEQvF2= NHu4coJUSU6JRWK=
CaR-1 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Pwb2lEPTB;M{OuPVgzOiEQvF2= M4rIUXNCVkeHUh?=
OE33 M1qwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS3Om9wUUN3ME2zOE4zQDV3IN88US=> NVrwUWg6W0GQR1XS
COLO-800 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DFTGlEPTB;M{SuN|Y1PyEQvF2= MYXTRW5ITVJ?
NB14 M3yyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX5b5ZKSzVyPUO0MlQ3QDRizszN NUHxcXRRW0GQR1XS
KURAMOCHI MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n3bmlEPTB;M{[uNVE6QCEQvF2= MVrTRW5ITVJ?
SW48 M4LIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN4LkK0O|Qh|ryP NE\kb3BUSU6JRWK=
Daoy M2jxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjZTFlKSzVyPUO2MlY2OzhizszN Mn\pV2FPT0WU
TGBC24TKB M{nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rUd2lEPTB;M{[uOlch|ryP NInoV5BUSU6JRWK=
DU-4475 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe5OHhKSzVyPUO2MlkxOzNizszN NGLn[5pUSU6JRWK=
SW1417 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHaTWM2OD1|OD6wOVUzKM7:TR?= MlLTV2FPT0WU
EFO-21 NYrmXFlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpSGlEPTB;M{iuPVM1QSEQvF2= MVLTRW5ITVJ?
MG-63 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\E[WlEPTB;M{muN|QzPCEQvF2= MV3TRW5ITVJ?
LC-2-ad MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXNV4VRUUN3ME2zPU42PTF{IN88US=> NFHSRnNUSU6JRWK=
NOMO-1 NUXH[5hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTN7LkiyO|Qh|ryP MkXLV2FPT0WU
COLO-741 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRyLkGzNFQh|ryP M3H0dnNCVkeHUh?=
BxPC-3 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrQTWM2OD12MD61Olg3KM7:TR?= NFXLPZFUSU6JRWK=
HSC-2 NIXvbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRyLkmxNVMh|ryP NEXHbXpUSU6JRWK=
UMC-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fJeGlEPTB;NEGuNlY{KM7:TR?= MkLPV2FPT0WU
HCC1937 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHTcI4zUUN3ME20Nk44QDR|IN88US=> M3rTcXNCVkeHUh?=
Calu-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlexTWM2OD12Mz6yN|gzKM7:TR?= M{TCXHNCVkeHUh?=
NCI-H1573 NX23PHpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR|LkO0O|ch|ryP NWToWWFpW0GQR1XS
SK-N-AS M{jQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm0TWM2OD12Mz62NFE6KM7:TR?= M{jyN3NCVkeHUh?=
PSN1 NHK2VlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfHTWM2OD12NT6yOVQ5KM7:TR?= MlzWV2FPT0WU
TE-11 M13SfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTR3LkS4OFIh|ryP NH\Y[nlUSU6JRWK=
NCI-H1155 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHN[lk2UUN3ME20OU45QTZ5IN88US=> NXjpd|BVW0GQR1XS
KM12 NXX1eXptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR3LkmwO|Yh|ryP NFXjWmlUSU6JRWK=
RO82-W-1 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnreW4{UUN3ME20Ok46QDJ{IN88US=> M4nu[HNCVkeHUh?=
SW1573 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXjRZhFUUN3ME20O{4{PzN4IN88US=> NIH4UIJUSU6JRWK=
CAKI-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rhUWlEPTB;NEiuNlg1PSEQvF2= MlfLV2FPT0WU
U-118-MG M{LYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\Vc2lEPTB;NEiuN|cxOiEQvF2= NIO5N|RUSU6JRWK=
KYSE-520 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR6LkSwNVYh|ryP MnG2V2FPT0WU
HT55 NX;zUGdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR7LkG0O|Qh|ryP Ml[2V2FPT0WU
ChaGo-K-1 M4j4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GyU2lEPTB;NEmuOFc6OyEQvF2= NWfvSlVTW0GQR1XS
IA-LM NVrlNY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml31TWM2OD13ND62N|IzKM7:TR?= M1\jUXNCVkeHUh?=
UACC-62 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3wTWM2OD13NT6xNFQ3KM7:TR?= NYflOHQ1W0GQR1XS
MKN7 NHzh[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;iPJFKSzVyPUW2MlAzQDVizszN M1rjXXNCVkeHUh?=
HPAF-II NHLiWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX6N2JKSzVyPUW2MlQxPzNizszN MYHTRW5ITVJ?
NTERA-S-cl-D1 M1\4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTV5Lke3PEDPxE1? NVzGWmkzW0GQR1XS
FTC-133 M3jRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTV6LkC5Olkh|ryP MWrTRW5ITVJ?
MHH-ES-1 M1m2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTV6LkS4NVQh|ryP NH3x[lNUSU6JRWK=
JVM-2 NH7RSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq5eXFKSzVyPUW4Mlk2ODZizszN Moi4V2FPT0WU
TCCSUP NGi0XZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[0NmlEPTB;NUmuOVI4QSEQvF2= M{THOnNCVkeHUh?=
COLO-824 NHvoRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTZyLkC3NVkh|ryP NFrFV3lUSU6JRWK=
647-V NFfFVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3njSWlEPTB;NkCuNVM1PyEQvF2= M3nwbHNCVkeHUh?=
HD-MY-Z MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lTWM2OD14MD61Nlk1KM7:TR?= Ml3EV2FPT0WU
LS-411N Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTZzLkO5NFMh|ryP NFn4XGZUSU6JRWK=
NCI-H596 M17PVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofsTWM2OD14Mj63OFk3KM7:TR?= NEjyOGVUSU6JRWK=
C-33-A Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHGTWM2OD14ND6wPVU4KM7:TR?= MWHTRW5ITVJ?
BHY Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXKZnJKSzVyPU[0MlEzPDVizszN NGTiTo5USU6JRWK=
KGN MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S5d2lEPTB;NkSuOVUyPCEQvF2= M2joe3NCVkeHUh?=
NCI-H1092 NWLpd|NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZ3LkCwPVUh|ryP MYrTRW5ITVJ?
MZ1-PC NHPpO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\XZ4N3UUN3ME22OU42PjR7IN88US=> MmezV2FPT0WU
LB831-BLC NHvPOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13OPGlEPTB;NkWuPFQ5OSEQvF2= NF7FfG5USU6JRWK=
SW620 NWjXVnZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHxZmFKSzVyPU[2MlIxOzlizszN M3\pPHNCVkeHUh?=
HuO-3N1 NFrFc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf0UnVYUUN3ME22PE4{OjN6IN88US=> NE\2RXZUSU6JRWK=
SK-HEP-1 NIe3dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHh[WJKSzVyPU[5Mlk1QDZizszN MmftV2FPT0WU
LCLC-103H NED4SY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTdyLk[3NFUh|ryP M1XFe3NCVkeHUh?=
KYSE-70 M3nSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vrTGlEPTB;N{CuO|g{PSEQvF2= NH2zcJBUSU6JRWK=
Mewo NFzVW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vKXWlEPTB;N{GuOVA2KM7:TR?= NU\pcmg4W0GQR1XS
COLO-668 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnKTWM2OD15MT64OFUyKM7:TR?= MXXTRW5ITVJ?
NCI-H522 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKwXmtKSzVyPUeyMlM1OTNizszN M2n5UXNCVkeHUh?=
NCI-H1437 NGjvTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELmXplKSzVyPUe0MlQxPDhizszN NYPLW2liW0GQR1XS
U-266 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTDToM3UUN3ME23OU41PTF4IN88US=> NEjRV4ZUSU6JRWK=
MC116 M4PHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTd3LkW3NFgh|ryP NHXYcGdUSU6JRWK=
PANC-10-05 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LEcmlEPTB;N{euOFI1OyEQvF2= MV;TRW5ITVJ?
KYSE-180 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TsfGlEPTB;N{euOVQ2PCEQvF2= NF;FeINUSU6JRWK=
JAR NEThNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTd7LkC1OFYh|ryP NVLS[HU4W0GQR1XS
CAL-62 NXfsZ2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\rRXRKSzVyPUiwMlA6PSEQvF2= Ml\vV2FPT0WU
A3-KAW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT0UJo1UUN3ME24NE4zOTV2IN88US=> NFi4U|hUSU6JRWK=
PANC-08-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\wTWM2OD16MT6xO|Y5KM7:TR?= MUnTRW5ITVJ?
HSC-3 NXnjS|RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i0VmlEPTB;OEOuN|A4OSEQvF2= MVzTRW5ITVJ?
HTC-C3 NHHweWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\MU3BXUUN3ME24N{41PzB{IN88US=> NWnwd2ljW0GQR1XS
KY821 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH21TW9KSzVyPUi0MlA5QTJizszN NHzLWFJUSU6JRWK=
DoTc2-4510 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTh2LkKxPFUh|ryP MV;TRW5ITVJ?
NCI-H1581 NIDZb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz0VoY{UUN3ME24OU41PjRzIN88US=> MkfNV2FPT0WU
KARPAS-299 NXLuXYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTh4LkG5O|ch|ryP M2WzSHNCVkeHUh?=
IST-MEL1 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTh4Lki4O|Ih|ryP MlfKV2FPT0WU
KP-N-YS Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfnWINKSzVyPUi5MlkxOjhizszN NEfv[IxUSU6JRWK=
KYSE-410 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofkTWM2OD17MT60NFQzKM7:TR?= NFnMXW9USU6JRWK=
TE-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvNTWM2OD17MT61OlEyKM7:TR?= NID0eYtUSU6JRWK=
SK-MEL-1 M2\3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPxT4dKSzVyPUmyMlkyODZizszN MUnTRW5ITVJ?
COLO-792 NYTjT251T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;KVWlEPTB;OUWuNlU3PCEQvF2= NWPmUW5UW0GQR1XS
SCH NUHQWYZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHeyZmJKSzVyPUm2MlM5PzdizszN MWDTRW5ITVJ?
NCI-H1792 NInFdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT4TWM2OD17Nj64PVkzKM7:TR?= MmSxV2FPT0WU
NCI-H2029 NYK1UFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn6XIl5UUN3ME25Ok46PTZ4IN88US=> MkXpV2FPT0WU
SW684 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTl6Lk[2OVQh|ryP Ml\FV2FPT0WU
NCI-H209 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HtS2lEPTB;MUCwMlEzOSEQvF2= M1iwOnNCVkeHUh?=
HLE MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2THSmlEPTB;MUC1MlI5OiEQvF2= MUTTRW5ITVJ?
GOTO MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXQfGNZUUN3ME2xNFcvPzd5IN88US=> MmDGV2FPT0WU
NCI-H1793 NXPoOGNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKzTWM2OD1zMEmuNlgh|ryP MUXTRW5ITVJ?
D-392MG NEjxcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnxVZdUUUN3ME2xNVcvOzl6IN88US=> M{fS[nNCVkeHUh?=
SW1990 NF;qNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW4fYFKSzVyPUGyNE46PTFizszN MVrTRW5ITVJ?
ML-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLyTWM2OD1zMkGuOlc3KM7:TR?= MkHMV2FPT0WU
NCI-H2452 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOyWVRKSzVyPUGyNk4zOSEQvF2= NHvkRlBUSU6JRWK=
SK-MEL-30 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1zMkOuNlQ1KM7:TR?= M37idnNCVkeHUh?=
SN12C NUDSSGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr0NWhKSzVyPUGyOE4yPzZizszN NF3FTmRUSU6JRWK=
NCI-H1770 NWnJcFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojCTWM2OD1zMkWuOVE1KM7:TR?= NHTLUFNUSU6JRWK=
SF268 NHnPWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF{Nj6xOVgh|ryP NUjoU5JkW0GQR1XS
BALL-1 M2f4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOwdIxHUUN3ME2xNlYvOjNizszN M2XNOHNCVkeHUh?=
COLO-679 NWHqNY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXkTWM2OD1zMk[uO|U{KM7:TR?= MnvPV2FPT0WU
A2780 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xN2NqUUN3ME2xNlgvQTh6IN88US=> NIL0SZpUSU6JRWK=
NCI-H1651 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrrNmhKSzVyPUGzNU4zPDNizszN NGL6XI9USU6JRWK=
NCI-H2087 NHjFSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF|MT60PFMh|ryP MV;TRW5ITVJ?
U-87-MG M1XpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF|Mz62NFQh|ryP M4\DSnNCVkeHUh?=
LB2518-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF|NT65PVMh|ryP M1m1WHNCVkeHUh?=
HCT-116 NEjSW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTiTWM2OD1zM{euNlE4KM7:TR?= M1i2dXNCVkeHUh?=
Ca9-22 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF|OT64N|Mh|ryP Mn7GV2FPT0WU
COR-L88 NIHSOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF2Mj6xOEDPxE1? NWTLVVVLW0GQR1XS
CP50-MEL-B M1nOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor1TWM2OD1zNESuOVAyKM7:TR?= MkXoV2FPT0WU
OVCAR-8 M2PZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DLSWlEPTB;MUS1MlY{PiEQvF2= MXTTRW5ITVJ?
SK-MEL-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uybGlEPTB;MUS3Mlg4QCEQvF2= NVvRRmZRW0GQR1XS
GT3TKB NFTDN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WzemlEPTB;MUS5MlkzQCEQvF2= MUnTRW5ITVJ?
KYSE-450 M3zGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzEPFRMUUN3ME2xOVEvPTN7IN88US=> M{DMW3NCVkeHUh?=
CAPAN-1 NYrHT21YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ZPWJKSzVyPUG1N{4xPjRizszN MWPTRW5ITVJ?
BEN MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF3Mz65Nlgh|ryP MV3TRW5ITVJ?
NCI-H1304 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjNdnRlUUN3ME2xOVQvPjl2IN88US=> NYLxeJBjW0GQR1XS
KU812 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF3OD62O|Qh|ryP MkPnV2FPT0WU
Capan-2 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF4MD61OVMh|ryP MUTTRW5ITVJ?
A673 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULQblIxUUN3ME2xOlEvPzB3IN88US=> M1rrbnNCVkeHUh?=
SAS NXfIVpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC2XZNOUUN3ME2xOlIvPjd6IN88US=> MlrPV2FPT0WU
NY MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF4NT6zNVQh|ryP MmP0V2FPT0WU
HCE-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF4Nj64OFUh|ryP M3PQUXNCVkeHUh?=
MDA-MB-231 NEfvS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\VNotbUUN3ME2xO|cvPTB|IN88US=> NHLId4ZUSU6JRWK=
no-10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITXWGRKSzVyPUG3PE4yOzRizszN MonKV2FPT0WU
MZ7-mel NEDrVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjwdFBKSzVyPUG3PE41PjdizszN NWLlSJN5W0GQR1XS
NCI-H82 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK2UJhKSzVyPUG4NE4yPjVizszN M1PVbnNCVkeHUh?=
CAL-72 NGTOenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3oTWM2OD1zOEWuNFU1KM7:TR?= M{fhdHNCVkeHUh?=
NCI-SNU-5 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7CTWM2OD1zOE[uPFQh|ryP MknUV2FPT0WU
OVCAR-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDCNlJKSzVyPUG4PE4{OzNizszN MUjTRW5ITVJ?
SCC-9 NXnDTFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPxdYhKSzVyPUG5NUDPxE1? NHfJXpBUSU6JRWK=
KYSE-150 NH7rPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1zOUGuPFg5KM7:TR?= NUWydphPW0GQR1XS
HT-29 NXTJRo1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjnTWM2OD1{MEGuNlEzKM7:TR?= M2fvfXNCVkeHUh?=
COLO-678 M3[5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwXos4UUN3ME2yNFEvPDVizszN MWfTRW5ITVJ?
NCI-H650 NET2c|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJyMj6xNFMh|ryP NUnve2dvW0GQR1XS
HuCCT1 NVPxcpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJyND6yNFgh|ryP M{DZNHNCVkeHUh?=
SW1116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknYTWM2OD1{MEeuNFc4KM7:TR?= NGC0bHdUSU6JRWK=
DBTRG-05MG NFnYblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJyNz65NFkh|ryP MXvTRW5ITVJ?
SW982 NEXCNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvTWM2OD1{MEeuPVQ5KM7:TR?= MYrTRW5ITVJ?
RCM-1 NWnafWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID5[XFKSzVyPUKxOE44PjJizszN Mo\JV2FPT0WU
COLO-320-HSR M1Hab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvSTWM2OD1{MU[uNVI2KM7:TR?= NF;1OJNUSU6JRWK=
KNS-42 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJzNj61O|Qh|ryP MVfTRW5ITVJ?
C2BBe1 Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ|MT65NFUh|ryP MkjuV2FPT0WU
CCRF-CEM NGr4SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\IdmNKSzVyPUK0N{44QTVizszN Mk[xV2FPT0WU
SH-4 M1vaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ2Nj6wPUDPxE1? M4nqfnNCVkeHUh?=
LS-1034 M{Xzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq2S2JKSzVyPUK0Ok4zPjZizszN NUfjeGdbW0GQR1XS
NCI-H2347 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPjc|dKSzVyPUK0O{44OTNizszN NGG2O|JUSU6JRWK=
RPMI-8866 M37TXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPVOngyUUN3ME2yOFkvOjdizszN MmGxV2FPT0WU
GAK NXnnUmZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjBdZVIUUN3ME2yOVMvODB{IN88US=> NGi0ZmlUSU6JRWK=
NB6 M{LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{juVWlEPTB;MkewMlEh|ryP MVzTRW5ITVJ?
COLO-680N MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vIZmlEPTB;MkeyMlUzPyEQvF2= MoLyV2FPT0WU
RERF-LC-MS NWHNb5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ5Nj6wNFch|ryP NXjkcVJZW0GQR1XS
TGBC11TKB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnJNoh1UUN3ME2yO|gvOTd6IN88US=> MlP1V2FPT0WU
C8166 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnhdmRKSzVyPUK3PE42ODZizszN NGHKTHNUSU6JRWK=
HDLM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XqU2lEPTB;Mkm0MlQxQSEQvF2= M3HDRXNCVkeHUh?=
IGR-1 M{nTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnjTWM2OD1{OUWuOlU6KM7:TR?= NVTxOXF4W0GQR1XS
FADU NGXUPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL6fXdKSzVyPUK5O{42OSEQvF2= M3zJfXNCVkeHUh?=
L-428 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37WO2lEPTB;Mkm3MlYyPiEQvF2= MnvRV2FPT0WU
LU-65 M4PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSzZY1KSzVyPUOwOE4{OiEQvF2= NG\jdGdUSU6JRWK=
HEL NGrhdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj1fZVKSzVyPUOwPU46QDNizszN MXvTRW5ITVJ?
NCI-H810 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;3OGlEPTB;M{GwMlU4KM7:TR?= M33GTnNCVkeHUh?=
C3A MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37icmlEPTB;M{GxMlgxOiEQvF2= NIm2W2pUSU6JRWK=
NCI-H630 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfLemZKSzVyPUOzNk4zQTRizszN Ml;jV2FPT0WU
KP-N-YN NGTWNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT5cWNLUUN3ME2zOFEvOTJ|IN88US=> NInmOVlUSU6JRWK=
MOLT-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN2Mj6zNlYh|ryP MXTTRW5ITVJ?
NCI-H1993 NVroe3BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDMTWM2OD1|NEKuN|Y2KM7:TR?= NELGT|JUSU6JRWK=
BE-13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnUTWM2OD1|NESuNVY4KM7:TR?= MmTkV2FPT0WU
IST-SL1 NF[wOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfHRY9nUUN3ME2zOFcvPDBzIN88US=> MXfTRW5ITVJ?
TE-9 NYOyTVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\JTWM2OD1|NkOuOVg6KM7:TR?= MUXTRW5ITVJ?
LU-135 NUnUNYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHxbZBnUUN3ME2zOlcvODN3IN88US=> Ml3EV2FPT0WU
T84 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz5XI5rUUN3ME2zO|QvPzF{IN88US=> MULTRW5ITVJ?
K-562 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN6Mz6zOkDPxE1? NIX3SnBUSU6JRWK=
SBC-5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD1TWM2OD1|OE[uPVg2KM7:TR?= NInsSmVUSU6JRWK=
NB17 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTZPJpKSzVyPUO5Nk42QTZizszN NXzYZ2hoW0GQR1XS
NCI-H2052 NFjQfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN7OD60O|Ih|ryP MUjTRW5ITVJ?
HCC38 NX3pZppET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRyMT61PVMh|ryP NF:x[HNUSU6JRWK=
NCI-H69 NIXmSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXQTWM2OD12NEGuNFg{KM7:TR?= M1S4THNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[4]
+ 展開

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
細胞試験: [2]
+ 展開
  • 細胞株: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • 濃度: 0, 0.3, 1 and 3 μM
  • 反応時間: 72 or 96 hours
  • 実験の流れ: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • 製剤: Formulated in 30% Captisol
  • 投薬量: 120 mg/kg
  • 投与方法: Orally administered
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
15% Captisol
17 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 480.39
化学式

C25H21N5O.2HCl

CAS No. 1032350-13-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 問題2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Related Antibodies

Akt信号経路図

Akt Inhibitors with Unique Features

相関Akt製品

Tags: MK-2206 2HClを買う | MK-2206 2HCl ic50 | MK-2206 2HCl供給者 | MK-2206 2HClを購入する | MK-2206 2HCl費用 | MK-2206 2HCl生産者 | オーダーMK-2206 2HCl | MK-2206 2HCl化学構造 | MK-2206 2HCl分子量 | MK-2206 2HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID